Noetik OCTO-VC AI foundation-model license (oncology)

Research partnerships Deployment Vendor source

Disclosed: Aug 2026 Verified: September 28, 2026 Partners: Noetik

Noetik says it met the first milestone of its five-year licensing agreement with GSK (announced January 2026, $50 million upfront capital and near-term milestones) and that GSK teams are using its OCTO-VC models for virtual cell experiments, patient stratification and H&E data enrichment.

$50 million upfront capital plus near-term milestones vendor claim

Source

Vendor Archive pending